Tirzepatide: A Dual-Action Medication for Type 2 Diabetes and Chronic Weight Management
Tirzepatide is a prescription medication that activates two naturally occurring hormone pathways: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These pathways influence blood-sugar regulation, appetite, digestion, and insulin release. FDA-approved tirzepatide products are marketed under different brand names for specific medical uses, including type 2 diabetes and chronic weight management. [91][92]
Tirzepatide can help improve blood-sugar control by increasing insulin release when blood glucose is elevated, reducing glucagon activity, and slowing stomach emptying. It may also help some people feel full sooner and remain satisfied for longer after eating. When prescribed for weight management, it should be used as part of a comprehensive plan that includes a reduced-calorie eating pattern, physical activity, and ongoing medical care.
FDA-Approved Uses
FDA-approved tirzepatide products have distinct indications. Mounjaro is approved as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Zepbound is approved for chronic weight management in eligible adults with obesity, or adults who are overweight and have at least one weight-related medical condition. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity, when used with a reduced-calorie diet and increased physical activity. [92][100]
- Improvement of blood-sugar control in adults with type 2 diabetes
- Chronic weight management for appropriately eligible adults
- Treatment of moderate to severe obstructive sleep apnea in adults with obesity
Dosage and Treatment Approach
Tirzepatide is administered as a subcutaneous injection once weekly. Treatment commonly begins with a lower introductory dose and is increased gradually under a prescriber’s direction. This stepwise approach is intended to help reduce gastrointestinal side effects as the body adjusts to treatment.
The correct dose depends on the prescribed product, the medical indication, treatment response, side effects, and other medications. Do not use a general dosing schedule found online, change the dose without medical guidance, or use tirzepatide more frequently than prescribed. Do not combine tirzepatide with another tirzepatide-containing product, GLP-1 receptor agonist, or weight-loss medication unless specifically directed by a qualified healthcare professional. [95][96]
Common Side Effects
The most common side effects are gastrointestinal and may include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, decreased appetite, or fatigue. These effects may be more noticeable when starting treatment or increasing the dose. Contact a healthcare professional if symptoms are severe, persistent, or interfere with eating, drinking, or daily activities.
Important Safety Information
Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodents. It should not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. People with a history of pancreatitis, gallbladder disease, severe digestive disorders, diabetic retinopathy, or kidney problems should discuss their full medical history with a prescribing clinician. [92][97]
Seek prompt medical care for severe or persistent abdominal pain, repeated vomiting, dehydration, symptoms of a serious allergic reaction, vision changes, or symptoms of low blood sugar. Low blood sugar is more likely when tirzepatide is taken with insulin or certain diabetes medications.
Compounded Tirzepatide Notice
FDA-approved tirzepatide products are not the same as compounded versions. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or manufacturing quality before they are dispensed. The FDA has reported concerns about fraudulent labeling, product quality, and dosing errors involving compounded GLP-1 medications, including tirzepatide. [64][93]